Pharmacokinetics

Pharmacokinetics is the study of what the body does to a drug: how a dose is absorbed, where it distributes, how it is chemically changed, and how it is finally removed.

8 frameworks, from 1930 to today · Pharmacology · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Pharmacokinetics is the study of what the body does to a drug: how a dose is absorbed, where it distributes, how it is chemically changed, and how it is finally removed1. Its practitioners ask a deceptively simple set of questions—how much drug reaches the blood, how long it stays there, and what determines its concentration at the moment it matters1. The field matters because the same dose that cures one patient can poison another, and the difference often lies not in the drug's action but in the body's handling of it. Where pharmacodynamics asks what a drug does to the body, pharmacokinetics asks what the body does to the drug, and the two together turn a vague notion of "dose" into a measurable, predictable quantity12.

From Folk Dosing to Measurable Concentration

For most of medical history, dosing was empirical. Physicians adjusted remedies by observation of effect and by tradition, with no way to know how much active substance was present in the blood. The intellectual groundwork for a quantitative approach came from chemistry and physiology in the nineteenth century. The isolation of active principles—morphine from opium in the early 1800s, for instance—made it possible to speak of a known quantity of a substance rather than an uncertain preparation. Physiologists meanwhile began to study how substances move through living organisms, and the idea took hold that a drug's effect depends on its concentration at the site of action, not merely on the amount swallowed.

The decisive shift came in the early twentieth century, when pharmacologists began to measure drug concentrations in blood and tissue and to describe their rise and fall over time. The word "pharmacokinetics" itself entered use in this period, and the field's central insight crystallized: the body treats a drug as a substance to be transported, distributed, metabolized, and excreted, and each of these processes follows patterns that can be described mathematically.

The Compartmental Model and the Language of Half-Life

The first great organizing idea was the compartmental model. Rather than tracking a drug through every organ, pharmacologists treated the body as one or a few well-mixed "compartments"—abstract volumes in which the drug is assumed to distribute evenly1. A one-compartment model treats the whole body as a single pool; a two-compartment model adds a peripheral pool that the drug enters and leaves more slowly1. The appeal was practical: a handful of parameters could describe a concentration–time curve, and the most famous of these, the half-life (the time for blood concentration to fall by half), became a standard measure of how long a drug persists.

The mathematics of this approach was formalized in the 1960s and 1970s, notably in the work of pharmacologists who adapted chemical kinetics to living systems. The compartmental framework made it possible to design dosing regimens—how often to give a drug, and how large a dose—so that concentration stayed within a therapeutic window. It also introduced the idea of steady state, the point at which drug entering the body balances drug leaving it, so that concentrations stabilize during repeated dosing1.

Clearance, Bioavailability, and the First-Pass Problem

A second wave of concepts gave the field its physiological vocabulary. Clearance is the volume of blood or plasma from which a drug is completely removed per unit time; it captures the combined efficiency of the liver, kidneys, and other eliminating organs. Volume of distribution describes how widely a drug spreads through the body relative to its concentration in plasma13. Together, clearance and volume of distribution determine half-life, and this relationship—half-life proportional to volume of distribution divided by clearance—became a cornerstone of the field1.

The bioavailability and first-pass framework addressed a problem that had long puzzled clinicians: why does the same amount of a drug given by mouth produce far less effect than when injected? The answer lay in incomplete absorption from the gut and in first-pass metabolism—the liver's removal of a portion of the drug before it ever reaches the general circulation45. Measuring bioavailability (the fraction of a dose that reaches the bloodstream unchanged) became essential for comparing formulations and routes of administration14. This framework, developed through the mid-twentieth century and refined as oral drug therapy expanded, explained why some drugs are useless by mouth and why dosing must differ by route.

Nonlinear Kinetics: When the Body's Machinery Saturates

The early models assumed that elimination processes work proportionally—double the concentration, double the rate of removal1. But some drugs showed a different pattern: as concentration rose, the rate of elimination stopped keeping pace, and small dose increases produced disproportionately large rises in blood concentration1. This is nonlinear, or saturable, kinetics, and it reflects the finite capacity of the enzymes and transporters that handle a drug1. The classic demonstration came with drugs such as phenytoin, whose metabolism saturates within the therapeutic range, so that a modest dose increase can push concentrations into toxic territory. Recognizing saturation changed clinical practice: for such drugs, dosing must be individualized and monitored, because the relationship between dose and concentration is no longer predictable by simple proportion1.

Therapeutic Drug Monitoring

The ability to measure drug concentrations in blood made possible therapeutic drug monitoring—the practice of adjusting doses by measuring plasma levels rather than relying on clinical impression alone6. It became established for drugs with narrow therapeutic windows, where the gap between effective and toxic concentrations is small: lithium for bipolar disorder, digoxin for heart failure, aminoglycoside antibiotics, and the immunosuppressant cyclosporine are standard examples17. Monitoring required reliable assays and an understanding of when to sample—at what point in the dosing interval the concentration is meaningful6. It turned pharmacokinetic theory into a bedside tool and made the case that individual patients differ enough to warrant measurement rather than assumption1.

Population Pharmacokinetics and the Individual Patient

A further problem emerged: patients are not identical, and a dosing regimen built for an average adult may fail in a child, an elderly patient, or someone with kidney disease1. Population pharmacokinetics addressed this by studying concentration data from many patients at once, using statistical models to separate the typical behavior of a drug from the variability between individuals and within the same individual over time. The approach, developed from the 1970s onward and greatly aided by computing power, identifies which patient characteristics—weight, age, kidney function, genetic makeup—explain differences in clearance and volume of distribution. It made possible Bayesian dose individualization, in which a patient's own measured concentrations are used to refine their predicted dosing. This is now central to clinical pharmacology, especially in specialized settings such as neonatal intensive care and transplant medicine.

Physiologically Based Modeling: Building the Body in Silico

Compartmental models are abstract; physiologically based pharmacokinetic (PBPK) modeling instead represents the body as a set of real organs connected by blood flow, each with its own volume and permeability. The approach has roots in the mid-twentieth century, when physiologists and pharmacologists began constructing flow-based descriptions of drug distribution, but it matured with computing power in the 1990s and 2000s. PBPK models can predict concentrations in specific tissues—the brain, the fetus, a tumor—and can be adapted across species and populations. Regulators now accept PBPK analyses in some drug development contexts, for instance to predict drug–drug interactions or to support dosing in populations that are hard to study directly, such as pregnant women or children.

Molecular and Pharmacogenomic Pharmacokinetics

The most recent layer of the field looks at the molecules that handle drugs. Drug-metabolizing enzymes—the cytochrome P450 family prominent among them—and drug transporters determine how fast a drug is cleared and where it goes. The discovery that these proteins vary between people, often because of inherited genetic differences, founded pharmacogenomic pharmacokinetics: the study of how a person's genes shape their handling of a drug. The classic example is the enzyme CYP2D6, whose activity varies widely across individuals and populations, affecting drugs from codeine to certain antidepressants. Genotyping can now predict whether a patient is a poor or rapid metabolizer and guide dose selection. This work connects pharmacokinetics to the broader field of pharmacogenomics and represents the field's move from describing average behavior to predicting individual behavior from molecular information8.

The Present: Model-Informed, Individualized, and Still Uncertain

Today's pharmacokinetics is model-informed and increasingly individualized. Compartmental analysis remains the everyday language of the clinic, while population approaches and PBPK modeling handle complexity and prediction1. Therapeutic drug monitoring and pharmacogenomic testing put individualization into practice for selected drugs6. The open questions are substantial: how to predict pharmacokinetics in populations rarely studied, how to integrate genetic, physiological, and environmental sources of variability into usable models, and how to make monitoring and genotyping practical at scale. The field's history is a story of learning to measure—first the drug in the blood, then the body's handling of it, then the molecules and genes behind that handling—and each measurement made the next question sharper.

References

  1. Pharmacokinetics (introduction, ADME, Compartmental analysis, Single-compartment model, Two-compartment model, Metrics, Bioavailability, Multi-compartment models, Clinical pharmacokinetics, Population pharmacokinetics, Modeling), Wikipedia
  2. Pharmacodynamics, Wikipedia
  3. Volume of distribution, Wikipedia
  4. Bioavailability, Wikipedia
  5. First pass effect, Wikipedia
  6. Therapeutic drug monitoring, Wikipedia
  7. Therapeutic index, Wikipedia
  8. Pharmacogenomics, Wikipedia

The frameworks of Pharmacokinetics

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1930-Present

    Compartmental pharmacokinetic modeling

    How does blood concentration change over time after a dose?

    Fly to its tower in Nousfarer

  2. 1950-Present
  3. 1950-Present
  4. 1960-Present

    Nonlinear (saturable) kinetics

    Why do small dose increases sometimes cause huge concentration jumps?

    Fly to its tower in Nousfarer

  5. 1965-Present

    Therapeutic drug monitoring

    When should a patient's drug level be measured and acted on?

    Fly to its tower in Nousfarer

  6. 1975-Present

    Population pharmacokinetics

    Why do patients given the same dose differ so much?

    Fly to its tower in Nousfarer

  7. 1990-Present

    Pharmacogenomic pharmacokinetics

    How do inherited genes change a person's handling of a drug?

    Fly to its tower in Nousfarer

  8. 1990-Present

    Physiologically based pharmacokinetic modelling

    How can tissue drug concentrations be predicted without measuring them?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Compartmental pharmacokinetic modelingBioavailability and first-pass metabo…Physiological clearance and volume-of…Nonlinear (saturable) kineticsTherapeutic drug monitoringPopulation pharmacokineticsPharmacogenomic pharmacokineticsPhysiologically based pharmacokinetic…

Beyond the field

Where Pharmacokinetics's ideas came from in other fields, and what they led to there: the strongest 12 of 46 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Pharmacokinetics is a planet in Nousfarer

Its city has a tower for each of these 8 frameworks. Land, walk in, and climb one concept at a time.

Land on Pharmacokinetics

Related fields

Fields its ideas are linked to

More in Pharmacology

See where Pharmacokinetics sits on the Map of Human Knowledge